“Randomized” means that it will be determined by chance which of the treatment groups you will be assigned to.

“Double-blind” means that neither the participant nor the research team will know whether a participant is taking the placebo or the investigational drug.

Participants will be treated with a low, middle, or high dose of Posiphen, or a placebo (a capsule that looks like the study drug but does not contain active ingredients).

Participants will help to determine the side effects of the drug and how the drug is metabolized by the human body (pharmacokinetics).

The primary outcome measures of this study are safety and tolerability, pharmacokinetics measured on serum and cerebrospinal fluid, and the dose effect on the production rate of Beta Amyloid 40.

The Shiley-Marcos Alzheimer’s Disease Research Center has a wide variety of opportunities for volunteers to participate in important research studies designed to discover ways to prevent, treat, and ultimately eradicate Alzheimer’s disease.

Visit the ADRC website for more clinical trials currently recruiting in San Diego.